Migraine medicines

Migraine attacks and prevention

An attack can combine headache with nausea and increased sensitivity to light or sound. Some migraines involve aura, consisting of transient neurological manifestations. Acute and preventive treatment have different time-related purposes: one concerns an episode, while the other forms part of a longer-term approach. These descriptions are not a simple scale of potency. They explain why very different presentations can be associated with migraine without being intended for the same stage of care. The disease name alone consequently does not establish the role of a particular medicine.

Triptans and the CGRP pathway

Triptans form a specific migraine medicine family. CGRP-related agents target a peptide or its receptor involved in migraine mechanisms, with differences between substances and preparations. A monoclonal antibody directed at a target is not merely another name for a small oral molecule. Official indications define the role of each product. General analgesics and selected medicines used in prevention may retain their own pharmacological family instead of all becoming migraine-specific agents within classification. This preserves the distinction between a documented use and the wider pharmaceutical identity of a substance.

Oral, nasal and injectable forms

Depending on the medicine, presentations can include oral, nasal or injectable forms. An orodispersible tablet remains distinct from a formulation intended for another route; its name describes a presentation characteristic rather than promising a particular onset. Injectable devices also have product-specific features. Content per unit, concentration and number of devices provide different information. These distinctions help pharmacies identify the precise form without creating automatic equivalence between acute and preventive treatments or assuming that two references share a role because both relate to migraine.

Frequently asked questions